Merck: A Pharma Giant Trading At A Decade-Low Valuation While Executing Its Post-Keytruda Playbook

Merck (MRK) looks undervalued amid 2028 Keytruda patent fears—strong Q3 results, pipeline wins, and 12x P/E suggest upside.
Business Insider

Buy Rating Affirmed on Merck’s Promising Oncology Pipeline and Keytruda’s Commercial Success

Goldman Sachs analyst Chris Shibutani has reiterated their bullish stance on MRK stock, giving a Buy rating today. Chris Shibutani has given his Buy rating due to a combination of factors surrounding ...
FiercePharma

Merck's Keytruda dealt another blow in prostate cancer but readies new challenge to AZ's Imfinzi

In a split showing for cancer powerhouse Merck, its immunotherapy Keytruda continued a losing streak in prostate cancer but chalked up a win to pressure an industry-first approval by AstraZeneca.
Investing

Formycon shares jump on first commercial agreement for Keytruda biosimilar

Investing.com -- Formycon shares jumped more than 6% on Thursday after the company announced its first commercial agreement for FYB206, its biosimilar candidate to Merck’s Keytruda. The deal covers ...